Erina E V, Megrelishvili R I, Pushkar' Iu T, Beliakova E V, Lediashova G A
Kardiologiia. 1979 Mar;19(3):46-52.
The hypotensive effect of visken-15, a blocking agent of the beta-adrenergic receptors, was studied in 7 patients with stage IB hypertensive disease, in 18 with stage IIA, and in 8 patients with stage IIB under conditions of in- and out-patient establishments. A favourable effect was produced in 81.5% of patients who were given one tablet of the drug once or twice a day. Treatment with visken-15 led to a decrease in systolic, diastolic and mean arterial pressure, in the rate of cardiac contractions, and in the blood minute volume at rest, in the orthostatic position, and during physical load. Visken-15 is marked by low toxicity, it is tolerated well and seldom causes side effects. The drug is recommended for the treatment of patients with early stages of hypertensive disease.
对7例IB期高血压病患者、18例IIA期患者和8例IIB期患者在门诊和住院条件下研究了β-肾上腺素能受体阻滞剂维斯肯-15的降压作用。每天服用1片该药1次或2次的患者中，81.5%产生了良好效果。使用维斯肯-15治疗导致收缩压、舒张压和平均动脉压降低，静息、直立位及体力负荷时的心脏收缩率和每分血容量降低。维斯肯-15毒性低，耐受性良好，很少引起副作用。该药推荐用于治疗高血压病早期患者。
